There is no specific disease being investigated
Conditions
Interventions
None listed
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: * Healthy volunteers between 18 and 55 years old; * BMI between 18.5 and 25; * Male or female; * If female: using oral contraceptives and not in hormone-free week during scanning.
Exclusion criteria
Exclusion criteria: * (History of) psychiatric treatment, for which prescription medication is used; * First-degree relative with (history of) schizophrenia or major depression; * (History) of neurological disorders (including stroke, convulsion, epilepsy) as well as concussion with loss of consciousness * Contraindications for S-ketamine (e.g. allergy for S-ketamine, or one of the inactive ingredients of this product, high BP (RRsystolic > 180 mmHg or diastolic >100 mmHg), use of xantiderivatives or methylergometrine); * Contraindications for 7T MRI (e.g. claustrophobia, osteosynthetic material, pacemaker, artificial cardiac valves); * (History of) drug (opiate, LSD, (meth)amphetamine, cocaine, solvents, cannabis, or barbiturate) or alcohol dependence; * Used psychotropic medication, or recreational drugs over a period of 1 week prior to each test session; * Used alcohol within the last 24 hours prior to each test session;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| * Change in levels of GABA, glutamate, and lactate in the mPFC; * phMRI signal in the mPFC. | — |
Secondary
| Measure | Time frame |
|---|---|
| * Functional connectivity, with the prefrontal cortex as important region of interest * Score on a VAS, to quantify the subjective effect of S-ketamine * CADSS to monitor changes in dissociative state due to placebo or ketamine administration. * Blood samples will be obtained at several time points to assess the plasma concentration of S-ketamine and its active metabolite norketamine. | — |
Countries
Netherlands
Outcome results
None listed